(3S,10S,14S)-1-[4-[[(2S)-4-Carboxy-2-[(2S)-4-Carboxy-2-(6-[18F] Fluoropyridin-3-Amido)Butanamido]Butanamido]Methyl]Phenyl]-3-[(Naphthalen-2-Yl)Methyl]-1,4,12-Trioxo-2,5,11,13-Tetraazahexadecane-10,14,16-Tricarboxylic Acid

3 trials 3 recruiting VVarious

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

3 Recruiting

0 Completed trials

3 Sponsors

6 Countries

Phase III

Phase II

Phase III: 2 Phase II: 1

Oversight events:

2 serious breaches across 1 trial

View oversight register →

Indications tested

Prostate cancer 1 Prostate cancer recurrent 1

Sponsors using this IMP

Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH 1 Karolinska University Hospital 1 Ospedale San Raffaele S.r.l. 1

All trials

3 total

[18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer Recruiting

2023-504026-19-01 Phase III 5 countries Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH
Fully hybrid 18F-PSMA PET/MRI as one-stop approach for the diagnosis of clinically significant prostate cancer Recruiting

2024-512859-21-00 Phase II 1 country Ospedale San Raffaele S.r.l.
A study to compare conventional "salvage" radiotherapy and individualized treatment based on results from PSMA PET/CT assessments in patient… Recruiting

2023-504917-54-00 Phase III 1 country Karolinska University Hospital

Showing 1–3 of 3 trials

← All drugs A–Z